免疫检查点抑制剂与肝脏:平衡治疗获益与不良事件
本文综述免疫检查点抑制剂(ICI)在肝细胞癌(HCC)和胆道癌中的疗效与肝脏毒性机制,以及肝外恶性肿瘤治疗中肝脏毒性的表现与管理。文章比较慢性肝炎/肝硬化患者与基础肝脏健康患者免疫相关肝损伤的特征、管理策略和结局,并讨论毒性及肝功能失代偿对患者预后的影响。
要点
- ICI 改善了肝细胞癌和胆道癌的治疗标准并提高患者生存。
- 缺乏经过验证的应答预测因子,需在生存获益与治疗相关肝毒性及慢性肝病失代偿风险之间权衡。
- 肝外恶性肿瘤 ICI 治疗相关的肝脏毒性表现和严重程度高度可变,准确评估对诊断和管理至关重要。
核心结论
- ICI 为肝细胞癌和胆道癌带来突破性生存改善,但需平衡预期生存获益与治疗相关肝毒性及基础慢性肝病失代偿风险。
- 肝外恶性肿瘤 ICI 治疗的肝脏毒性表现和严重程度高度可变,准确评估对诊断和管理至关重要。
研究设计与样本
- 本文为 Recent Advances 综述,概述抗癌免疫治疗在肝脏肿瘤中的疗效与毒性机制及肝外恶性肿瘤的肝脏毒性。
- 文章比较慢性肝炎/肝硬化患者与基础肝脏健康患者免疫相关肝损伤的特征、管理策略和结局。
主要发现
- ICI 改善了肝细胞癌和胆道癌数十年未变的治疗标准并提高患者生存。
- 肝细胞癌和胆道癌常发生于肝脏炎症和基础功能受损背景下,缺乏经过验证的应答预测因子。
- 肝外恶性肿瘤 ICI 治疗相关的肝脏毒性表现和严重程度高度可变。
- 文章讨论了毒性及肝功能失代偿如何影响肝脏肿瘤和肝外恶性肿瘤患者的预后。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors (ICI) have led to breakthrough improvements in the management of malignancy including hepatocellular (HCC) and biliary tract cancer, improving decades-old standards of care and increasing patient survival. In both liver tumour types, which commonly arise in the context of liver inflammation and underlying functional impairment, the lack of validated predictors of response underscores the need to balance predicted gains in survival with risk of treatment-related hepatoxicity and decompensation of underlying chronic liver disease.In addition, the liver is implicated in the toxicity associated with ICI therapy for non-liver cancers, which exhibits a high degree of variability in presentation and severity. An accurate assessment is mandatory for the diagnosis and management of ICI-induced liver injury.In this Recent Advances article, we provide an overview of the mechanisms of efficacy and toxicity of anticancer immunotherapy in liver tumours and liver toxicity in extrahepatic malignancies.We compare and contrast characteristics, management strategies and outcomes from immune-related liver injury in patients with chronic hepatitis/cirrhosis or with an underlying healthy liver and discuss the latest findings on how toxicity and decompensation may impact the outlook of patients with liver tumours and extrahepatic malignancies offering insights into the future directions of clinical research and practice in the field.
引用
- De Martin E, Fulgenzi CAM, Celsa C, et al. Immune checkpoint inhibitors and the liver: balancing therapeutic benefit and adverse events. Gut. 2025. PMID: 39658265. doi:10.1136/gutjnl-2024-332125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。